A Phase 3 interventional study of SKY0402 and Bupivacaine HCl in Pain, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 15 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-16.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies testing bupivacaine in Pain — 19 open to participants now, 19 under way, 3 of them phase 3. Bupivacaine · Pain.
Among the 146 studies testing bupivacaine in Pain, this one is the 21st largest by enrollment, is one of 8 that started in 2008, is one of 17 in phase 3, and was the 14th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →19 of the 146 studies testing bupivacaine in Pain are open now, in 5 countries. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18+
Tanta University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 40–75
Ain Shams University · Sites in Egypt
Ages 18–40 · Women only
Children's Hospital of Orange County · Sites in United States
Ages 7–17 · Healthy volunteers
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 20 · Phase 3 22 · Phase 4 55
First in 2002; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 63 across the 146 interventional studies. Of the 102 that completed or were terminated, 53 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 146 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
29 studies in Pain by Pacira BioSciences, Inc.: none open now, none under way, none of them phase 3. Of 29 finished, 26 (90%) have results posted.
Among the 29 studies in Pain by Pacira BioSciences, Inc., this one is the 11th largest by enrollment, is one of 4 that started in 2008, is one of 8 in phase 3, and was the 5th registered.
Pacira BioSciences, Inc.’s Pain studies by the year they started, since 2007.
8 of the studies testing bupivacaine in Pain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07631416Sohag UniversityLumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia | 2026-11-28 |
| NCT06004882M.D. Anderson Cancer CenterPeripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study | 2027-01-31 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 146 studies testing bupivacaine in Pain, from their registry updates:
Among Pacira BioSciences, Inc.’s 29 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare costs.
This is a phase 3 study conducted to evaluate the safety and efficacy of a single local administration of 300 mg of SKY0402 compared with 100 mg of conventional, commercially-available bupivacaine HCl (i.e. Marcaine 0.5% with epinephrine) administered locally into the implant pocket of each breast for postoperative analgesia in subjects undergoing bilateral, cosmetic, sub-muscular, breast augmentation under general anesthesia (endotracheal or otherwise). A total of 600 mg of SKY0402 or 200 mg bupivacaine HCl per subject is therefore administered. Post-operative assessments were conducted including adverse event and serious adverse event monitoring through Day 30.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A subject will not be eligible for the study if she meets any of the following criteria:
Use of any of the following medications within the times specified before surgery:
Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes, co-morbid conditions associated with an status such as blood dyscrasias, /AIDS, or recent chemotherapy.
In addition, the subject will be ineligible to receive study drug if she meets the following criteria during surgery:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)
Drug: SKY0402
A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)
Drug: Bupivacaine HCl
600mg SKY0402 instilled into breast pocket during surgery
Also known as: EXPAREL
200mg Bupivacaine HCl instilled into breast pocket during surgery
Also known as: Marcaine 0.5% with epinephrine
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores
Assessments of postoperative pain included pain intensity at rest (using the NRS at rest \[NRS-R\] and with activity \[using the NRS-A\]) where the prescribed activity was raising both arms. Pain intensity was assessed on a scale of 0 to 10, where 0=no pain and 10=worst possible pain.
Time frame: through 72 hours
Number of Participants With Adverse Events
Time frame: 30 days
| Milestone | SKY0402 | Bupivacaine HCl |
|---|---|---|
| Started | 66 | 70 |
| Completed | 64 | 70 |
| Not completed | 2 | 0 |
Assessments of postoperative pain included pain intensity at rest (using the NRS at rest \[NRS-R\] and with activity \[using the NRS-A\]) where the prescribed activity was raising both arms. Pain intensity was assessed on a scale of 0 to 10, where 0=no pain and 10=worst possible pain.
| Units on a scale*hours | SKY0402 | Bupivacaine HCl |
|---|---|---|
| Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores | 441 ± 163 | 467 ± 181 |
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SKY0402 | — | 0/64 (0%) | 48/66 (72.7%) |
| Bupivacaine HCl | — | 0/70 (0%) | 51/70 (72.9%) |
| Event | SKY0402 | Bupivacaine HCl |
|---|---|---|
| nauseaGastrointestinal disorders | 29/66 | 37/70 |
| vomitingGastrointestinal disorders | 10/66 | 14/70 |
| ConstipationGastrointestinal disorders | 11/66 | 13/70 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 10/66 | 11/70 |
| TachycardiaCardiac disorders | 3/66 | 7/70 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/66 | 0/70 |
| InsomniaPsychiatric disorders | 6/66 | 4/70 |
| HeadacheNervous system disorders | 2/66 | 5/70 |
| ChillsGeneral disorders | 4/66 | 2/70 |
| HypoaesthesiaNervous system disorders | 4/66 | 3/70 |
| Age, Categorical(Participants) | SKY0402 | Bupivacaine HCl | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 66 | 70 | 136 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | SKY0402 | Bupivacaine HCl | Total |
|---|---|---|---|
| Mean | 30.8 ± 7.3 | 30.6 ± 7.6 | 30.7 ± 7.4 |
| Sex: Female, Male(Participants) | SKY0402 | Bupivacaine HCl | Total |
|---|---|---|---|
| Female | 66 | 70 | 136 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | SKY0402 | Bupivacaine HCl | Total |
|---|---|---|---|
| United States | 66 | 70 | 136 |
The record gives a start of Nov 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 4 years 11 months after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine